Literature DB >> 15854808

Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug.

Siv Jönsson1, Mats O Karlsson.   

Abstract

Methods for optimizing dosing strategies for individualization with a limited number of discrete doses, in terms of maximizing the expected utility of treatment or responder probability, are presented. The optimality criteria require models for both beneficial and adverse effects that are part of the utility definition and published population models describing those effects for oxybutynin (urge urinary incontinence episodes per week and severity of dry mouth, respectively) were used for illustration. Dosing strategies with two dosing categories were defined in terms of sizes of the daily doses (low and high dose) and the proportion of patients that can be expected to be preferentially treated at the low dose level. Utility and responder definitions were varied to investigate the influence on the resulting dosing strategy. By minimizing a risk function, describing the seriousness of deviations from the predefined target, optimal dosing strategies were estimated using mixture models in NONMEM. The estimated dose ranges for oxybutynin were similar to those recommended. The optimal individualization conditions were dependent on the definitions of responder and utility. The predicted gain of individualization given utility and responder definitions used was greater, when a responder criteria was maximized compared with maximizing utility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15854808     DOI: 10.1016/j.ejps.2005.02.004

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  4 in total

1.  Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats.

Authors:  Ashraf Yassen; Erik Olofsen; Jingmin Kan; Albert Dahan; Meindert Danhof
Journal:  Pharm Res       Date:  2007-10-04       Impact factor: 4.200

2.  Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms.

Authors:  Anna-Karin Hamberg; Lena E Friberg; Katarina Hanséus; Britt-Marie Ekman-Joelsson; Jan Sunnegårdh; Anders Jonzon; Bo Lundell; E Niclas Jonsson; Mia Wadelius
Journal:  Eur J Clin Pharmacol       Date:  2013-01-11       Impact factor: 2.953

Review 3.  Translational PK-PD modeling in pain.

Authors:  Ashraf Yassen; Paul Passier; Yasuhisa Furuichi; Albert Dahan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

4.  Characterizing variability in warfarin dose requirements in children using modelling and simulation.

Authors:  Anna-Karin Hamberg; Mia Wadelius; Lena E Friberg; Tina T Biss; Farhad Kamali; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.